

Michigan MEDICATION SECTION PRALIDOXIME

Initial Date: 07/19/2023

Revised Date: Section: 9-39R

Pralidoxime

Pharmacological Category: Cholinesterase reactivator

Routes: IV/IM

Indications:

1. Exposure to organophosphate or nerve agents

Expected effects:

1. Decrease in symptoms

Side effects:

- 1. Blurred vision
- 2. Headache
- 3. Dizziness
- 4. Nausea

Notes:

- 1. This medication may be part of a Nerve Agent (NA) Antidote kit.
- 2. When not part of an NA kit, 600 mg pralidoxime (along with 2 mg Atropine) will be administered in place of each NA kit that was to be administered.

Dosing: NERVE AGENT/ORGANOPHOSPHATE PESTICED ESPOSURE

Indication: Symptomatic nerve agent or organophosphate pesticide exposure when a NA Antidote Kt is not available.

Adults and Pediatrics administer:

1. Pralidoxime 600 mg IV/IM for every one (1) NA Kit as required on Chart below.

MCA Name: HEMS, Inc. (WW/DR) MCA Board Approval Date: 2/8/2024 MCA Implementation Date: 3/1/2024

MDHHS Approval: 7/19/23



Michigan MEDICATION SECTION PRALIDOXIME

Initial Date: 07/19/2023

Revised Date: Section: 9-39R

	Clinical Findings	Signs/Symptoms	Required Conditions	NA Kits To Be Delivered
SELF-RESCUE	Threshold Symptoms	 Dim vision Increased tearing Runny nose Nausea/vomiting Abdominal cramps Shortness of breath 	Threshold Symptoms -and- Positive evidence of nerve agent or OPP on site Medical Control Order	1 NA Kit (self-rescue)
ADULT PATIENT > 8 years of age	Mild Symptoms and Signs	 Increased tearing Increased salivation Dim Vision Runny nose Sweating Nausea/vomiting Abdominal cramps Diarrhea 	Medical Control Order	1 NA Kit
	Moderate Symptoms and Signs	Constricted pupilsDifficulty breathingSevere vomiting	Constricted Pupils	2 NA Kits
	Severe Signs	Constricted pupilsUnconsciousnessSeizuresSevere difficulty breathing	Constricted Pupils	3 NA Kits (If 3 NA Kits are used, administer 1st dose of available benzodiazepine)

MCA Name: HEMS, Inc. (WW/DR) MCA Board Approval Date: 2/8/2024 MCA Implementation Date: 3/1/2024

MDHHS Approval: 7/19/23



Michigan MEDICATION SECTION PRALIDOXIME

Initial Date: 07/19/2023

Revised Date: Section: 9-39R

PEDIATRIC < 8 years of age	Pediatric Patient with Non-Severe Signs/ Symptoms	 Mild or moderate symptoms as above 	Threshold Symptoms -and- Positive evidence of nerve agent or OPP on site Medical Control Order	1 NA Kit
	Pediatric Patient with Severe Signs/ Symptoms	 Constricted pupils Unconsciousness Seizures Severe difficulty breathing 	Severe breathing difficulty Weakness	1 NA Kit

Used in the Following Protocols

Nerve Agent/Organophosphate Pesticide Exposure (Section 10 Special Operations)

MCA Name: HEMS, Inc. (WW/DR) MCA Board Approval Date: 2/8/2024 MCA Implementation Date: 3/1/2024

MDHHS Approval: 7/19/23